NEWS

The guideline is directed to Industry, Investigators, and Institutional Review Boards.

A lot of clinical research started against COVID-19. Some of them are new, some of them are old drug and vaccines.

Vaccines:

1. Altimmune’s intranasal coronavirus vaccine
2. INO-4800 by Inovio Pharmaceuticals and Beijing Advaccine Biotechnology
3. NP-120 (Ifenprodil) by Algernon Pharmaceuticals
4. APN01 by University of British Columbia and APEIRON Biologics
5. mRNA-1273 vaccine by Moderna and Vaccine Research Center
6. Avian Coronavirus Infectious Bronchitis Virus
   Read More…

One study was initiated by Gilead in Spain and looks for IV Remdesevir in 2 age cohorts. The other study in USA compares Remdesevir with Placebo. The third study in Europe compares Remdesivir with an HIV drug combination (Ritonavir/Lopinavir) and HIV drug combination + IFN-Beta arms. The vaccine study is done in USA.

The Medical Research Council has revealed details of how it monitors its grantees to ernsure that all clinical trials it funds are registered and report their results.
Please read the news from this link.

According to the news in Nature and an article in Cell, this is the first hashtag#antibiotic developed by artificial intelligence from scratch..

The first virtual medial congress; 4th National Clinical Research Congress is finalized with 715 registered participants and 172 online live questions (excluding good wish messages). Several panels are organized with simultaneous connections to speakers in Turkey and abroad at the same time.

A 2007 regulation in the USA tells that all sponsors has to publish the results of finished clinical trials in one year. But the reality is quite different. Two articles published in Lancet and Science tells the story.

4th. Turkish Virtual Clinical Research Congress program and related information is attached.

4th. Turkish Virtual Clinical Research Congress program and related information is attached.

According to an article in NATURE, the number of authors in scientific journals is increasing rapidly. Between 2009 and 2013, 573 manuscripts listing 1,000 co-authors or more were published and this figure has risen to 1,315 papers over the past 5 years.